Drugs / Triamcinolone Acetonide
Triamcinolone Acetonide
also known as
Kenalog · Zilretta · Kenacort-A · Kenalog - 40 · TAC · TAC-PF · Triamcinolone · CLS-TA · +40 more
Regulatory milestones approvals, filings & regulatory actions · 8 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | ZILRETTA | — | 2019-12-23 | fda.gov ↗ |
| Label expansions (4) | US (FDA) | NASACORT ALLERGY 24 HOUR | — | 1997-09-26 – 2013-10-11 | fda.gov ↗ |
| Label expansion | US (FDA) | AZMACORT | — | 1996-10-30 | fda.gov ↗ |
| Label expansion | US (FDA) | NASACORT | — | 1996-05-20 | fda.gov ↗ |
| Approved | US (FDA) | TRIAMCINOLONE ACETONIDE | — | 1958-10-23 | fda.gov ↗ |
Trials 178 · started per year
today
US approved 1958
1
2
4
4
11
6
9
5
4
3
4
2
3
3
8
4
10
5
10
14
8
6
15
14
15
7
1957195819591960196119621963196419651966196719681969197019711972197319741975197619771978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 06 trials | ||||||
| Phase 0 | NCT07825155 | Mar → Jun 2026 overdue | carpal tunnel syndrome | Tanta University | Recruiting | No outcome recorded |
| Phase 0 | NCT06634823 | Dec 2024 → Jun 2026 overdue | laryngeal disorder | Medical University of South Carolina | Recruiting | No outcome recorded |
| Phase 0 | NCT04690608 | Dec 2024 | retinal edema | Tanta University | Unknown | No outcome recorded |
| Phase 0 | NCT07145008 | Sep 2024 → Jun 2025 overdue | macular retinal edema, uveitis | University of Baghdad | Recruiting | No outcome recorded |
| Phase 0 | NCT03445611 | Sep → Oct 2019 | osteoarthritis, knee | Loma Linda University | Withdrawn | No outcome recorded |
| Phase 0 | NCT00411333 | Jul 2006 → Jul 2009 | diabetic retinopathy | National Eye Institute (NEI) | Completed | No outcome recorded |
| Phase 113 trials | ||||||
| Phase 1 | NCT05906433 | Jun 2023 → Jun 2025 | osteoarthritis, knee | Foundation for Orthopaedic Research and Education | Completed | No outcome recorded |
| Phase 1 | NCT06681090 | Mar → Sep 2023 | lichen planus, oral | Al-Azhar University | Completed | No outcome recorded |
| Phase 1 | NCT04598542 | Oct → Dec 2020 | — | Biosplice Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04261049 | Aug 2020 → Jan 2022 | osteoarthritis, knee | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 1 | NCT04658836 | Feb 2020 → Aug 2021 | acoustic neuroma | Medical University of Vienna | Completed | No outcome recorded |
| Phase 1 | NCT04831255 | Jun 2019 → Aug 2023 | frozen shoulder | University of Virginia | Terminated | No outcome recorded |
| Phase 1 | NCT03627741 | Jun 2018 → Jul 2022 | fibromatosis | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT03248856 | Oct 2017 → Dec 2020 | hearing loss disorder | Christoph Arnoldner | Completed | No outcome recorded |
| Phase 1 | NCT00476918 | Jul 2006 → Dec 2007 | diabetic macular edema | Heidelberg University | Unknown | No outcome recorded |
| Phase 1 | NCT00915837 | Jun 2005 → Apr 2009 | diabetic macular edema | SurModics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00371410 | Apr 2005 → Oct 2007 | diabetic macular edema | Samsung Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT00101764 | Jan 2005 → May 2008 | diabetic retinopathy, macular degeneration, retinal vein occlusion | National Eye Institute (NEI) | Completed | No outcome recorded |
| Phase 1 | NCT00071227 | Oct 2003 → Aug 2007 | macular degeneration, retinal vein occlusion | National Eye Institute (NEI) | Completed | No outcome recorded |
| Phase 1/26 trials | ||||||
| Phase 1/2 | NCT06681688 | Jul 2024 → Jun 2025 overdue | cataract | Inder Paul Singh, M.D. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06230146 | May 2024 → Jan 2026 | keloid | Assiut University | Unknown | No outcome recorded |
| Phase 1/2 | NCT04326959 | Sep 2020 | keloid | PT. Prodia Stem Cell Indonesia | Unknown | No outcome recorded |
| Phase 1/2 | NCT01789320 | Feb 2013 → Mar 2015 | intermediate uveitis, panuveitis, posterior uveitis | Clearside Biomedical, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT00801450 | Sep 2007 → Dec 2008 | diabetic macular edema | University of Sao Paulo | Unknown | No outcome recorded |
| Phase 1/2 | NCT00407849 | Oct 2006 → Dec 2007 | diabetic retinopathy | Federal University of São Paulo | Unknown | No outcome recorded |
| Phase 234 trials · 1 met primary · 4 missed | ||||||
| Phase 2 | NCT07814677 | Sep 2026 → Nov 2028 expected | sudden hearing loss disorder | Eye & ENT Hospital of Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07714525 | May 2026 → May 2027 expected | chronic rhinosinusitis, nasal cavity polyp | Deraya University | Recruiting | No outcome recorded |
| Phase 2 | NCT07540728 | Apr 2026 → Apr 2028 expected | sudden hearing loss disorder | Eye & ENT Hospital of Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07713329 | Mar → Jun 2026 | pleural empyema, respiratory tract infectious disorder | Delta University for Science and Technology | Completed | No outcome recorded |
| Phase 2 | NCT07134075 | Aug 2025 → Aug 2027 expected | sudden sensorineural hearing loss | Eye & ENT Hospital of Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06734975 | Jul 2025 → Dec 2026 expected | polyp of vocal cord | Rutgers, The State University of New Jersey | Recruiting | No outcome recorded |
| Phase 2 | NCT04744675 | May → Jul 2024 overdue | complex regional pain syndrome | Ottawa Hospital Research Institute | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06237153 | Nov 2023 → Dec 2025 overdue | osteoarthritis, hand | Marie Badalamente | Recruiting | No outcome recorded |
| Phase 2 | NCT05512962 | Aug 2022 → Nov 2023 | diabetic macular edema | Oxular Limited | Completed | No outcome recorded |
| Phase 2 | NCT04331002 | Aug 2020 → Jul 2022 | — | Austin V Stone | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT04469075 | Jul 2020 → Jul 2026 overdue | glioblastoma, toxic dermatosis | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04002362 | Nov 2019 → Jan 2025 | childhood onset asthma | Emory University | Completed | No outcome recorded |
| Phase 2 | NCT02637323 | Nov 2015 → Sep 2016 | osteoarthritis, knee | Pacira Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 2 | NCT02221453 | Sep 2015 → Dec 2016 | diabetic macular edema | Unity Health Toronto | Completed | No outcome recorded |
| Phase 2 | NCT02465606 | Jul 2015 → May 2016 | atopic eczema | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT02303184 | Jan 2015 → Mar 2016 | macular retinal edema, retinal vein occlusion | Clearside Biomedical, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02255032 | Oct 2014 → Dec 2015 | anterior uveitis, intermediate uveitis, macular retinal edema, panuveitis +1 | Clearside Biomedical, Inc. | Completed | Met primary |
| Phase 2 | NCT02116972 | Apr 2014 → Nov 2015 | osteoarthritis, knee | Pacira Pharmaceuticals, Inc | Completed | Missed primary |
| Phase 2 | NCT01692756 | Mar 2013 → Feb 2017 | — | Cale Jacobs | Completed | Missed primary |
| Phase 2 | NCT01897259 | Mar 2012 → Jun 2019 | epicondylitis | Christine M. Kleinert Institute for Hand and Microsurgery | Unknown | No outcome recorded |
| Phase 2 | NCT07161778 | Oct 2011 → Sep 2020 | castration-resistant prostate carcinoma | Barts & The London NHS Trust | Completed | No outcome recorded |
| Phase 2 | NCT00890968 | Apr → Jun 2009 | hand dermatosis | ZARS Pharma Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01797432 | Mar 2009 → Nov 2014 | alopecia areata | University of Minnesota | Completed | No outcome recorded |
| Phase 2 | NCT00473083 | Jan 2009 → Dec 2012 | exanthem | British Columbia Cancer Agency | Completed | Missed primary |
| Phase 2 | NCT00692614 | Jun → Nov 2008 | macular retinal edema | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 2 | NCT00874744 | Mar → Sep 2008 | diabetic macular edema | Federal University of Goiás | Completed | No outcome recorded |
| Phase 2 | NCT01051648 | Dec 2007 → Feb 2008 | cataract, vitreous disorder | Cairo University | Completed | No outcome recorded |
| Phase 2 | NCT00484679 | May 2007 → Jun 2009 | alopecia areata | University of Minnesota | Completed | No outcome recorded |
| Phase 2 | NCT00464347 | Jan → Sep 2007 | age-related macular degeneration | National Eye Institute (NEI) | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00231023 | Sep 2005 → May 2006 | diabetic retinopathy | National Eye Institute (NEI) | Completed | No outcome recorded |
| Phase 2 | NCT00229918 | Sep 2005 → Sep 2006 | diabetic retinopathy | Edward Hines Jr. VA Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT00369486 | Dec 2004 → Jun 2006 | diabetic macular edema | Jaeb Center for Health Research | Completed | Missed primary |
| Phase 2 | NCT00140803 | Oct 2003 → Jan 2007 | age-related macular degeneration | Manhattan Eye, Ear & Throat Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00369863 | Jun 2002 → Jun 2003 | diabetic macular edema | Shahid Beheshti University of Medical Sciences | Completed | No outcome recorded |
| Phase 2/314 trials · 1 met primary · 1 missed | ||||||
| Phase 2/3 | NCT06988527 | May 2025 → Jun 2026 overdue | atrophic lichen planus, oral erosive lichen | Dar Al Uloom University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT03607175 | Jul 2023 → Sep 2025 | chronic rhinosinusitis, nasal cavity polyp | Marina Boruk | Unknown | No outcome recorded |
| Phase 2/3 | NCT05535738 | Nov 2022 → Jan 2027 expected | allergic contact dermatitis | Wei-Che Ko | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT05337332 | Apr 2022 → May 2023 | central serous chorioretinopathy, cystoid macular edema, pars planitis | Benha University | Unknown | No outcome recorded |
| Phase 2/3 | NCT05567081 | Jun 2021 → Apr 2022 | ulnar neuropathy | Tanta University | Completed | No outcome recorded |
| Phase 2/3 | NCT04744623 | Sep → Dec 2020 | mucous membrane pemphigoid | Tanta University | Unknown | No outcome recorded |
| Phase 2/3 | NCT05413330 | Sep 2020 → Jan 2022 | cataract, type 2 diabetes mellitus | Damascus University | Completed | No outcome recorded |
| Phase 2/3 | NCT05737173 | Aug 2020 → Sep 2022 | osteoarthritis, knee | Queen Savang Vadhana Memorial Hospital, Thailand | Completed | No outcome recorded |
| Phase 2/3 | NCT02328118 | Feb 2015 → Mar 2017 | proliferative diabetic retinopathy | JUNYAN ZHANG | Unknown | No outcome recorded |
| Phase 2/3 | NCT00853905 | Feb 2009 → Dec 2011 | glaucoma | Wills Eye | Completed | No outcome recorded |
| Phase 2/3 | NCT00532142 | Apr 2005 → Aug 2009 | central retinal vein occlusion | Rudolf Foundation Clinic | Completed | Met primary |
| Phase 2/3 | NCT00443521 | Mar 2005 → Jul 2006 | diabetic retinopathy | University of Sao Paulo | Completed | No outcome recorded |
| Phase 2/3 | NCT00148551 | Jan 2004 → Mar 2008 | age-related macular degeneration | Canadian Retinal Trials Group | Unknown | Missed primary |
| Phase 2/3 | NCT00305630 | Jul 2002 → Nov 2005 | age-related macular degeneration, choroidal neovascularization | Johns Hopkins University | Completed | No outcome recorded |
| Phase 330 trials · 2 met primary · 2 missed | ||||||
| Phase 3 | NCT07832552 | May → Dec 2026 expected | — | Harrow Inc | Enrolling by invitation | No outcome recorded |
| Phase 3 | NCT07189572 | Oct 2025 → Aug 2027 expected | otitis media with effusion | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06524323 | Sep 2024 → Aug 2026 overdue | prurigo nodularis | Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06269705 | Feb 2024 → Dec 2026 expected | osteoarthritis | Pacira Pharmaceuticals, Inc | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06605911 | Jun → Aug 2023 | lichen planus, oral | Shaymaa Hussein Rafat Kotb | Completed | No outcome recorded |
| Phase 3 | NCT04468542 | Jan 2021 → Dec 2022 | — | University of South Florida | Unknown | No outcome recorded |
| Phase 3 | NCT04347733 | May 2017 → Mar 2019 | frozen shoulder | Veterans Health Service Medical Center, Seoul, Korea | Completed | No outcome recorded |
| Phase 3 | NCT03097315 | Apr 2017 → Jan 2018 | anterior uveitis, intermediate uveitis, panuveitis, posterior uveitis | Clearside Biomedical, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03046446 | Feb 2017 → Jul 2018 | osteoarthritis, knee | Pacira Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 3 | NCT02447185 | Jun 2015 → Dec 2020 | proliferative diabetic retinopathy | JUNYAN ZHANG | Unknown | No outcome recorded |
| Phase 3 | NCT02357459 | Jan 2015 → Jan 2016 | osteoarthritis, knee | Pacira Pharmaceuticals, Inc | Completed | Met primary |
| Phase 3 | NCT02873026 | Oct 2014 → Mar 2020 | — | Moorfields Eye Hospital NHS Foundation Trust | Completed | Missed primary |
| Phase 3 | NCT01447160 | Oct 2011 → Apr 2012 | — | Federal University of São Paulo | Unknown | No outcome recorded |
| Phase 3 | NCT01572350 | Oct 2010 → Dec 2013 | diabetic macular edema | Hospital Universitario de Canarias | Completed | No outcome recorded |
| Phase 3 | NCT01095809 | Apr 2010 → Apr 2013 | uveitis | Hospital Clinic of Barcelona | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT00600301 | Jan 2008 | diabetic macular edema | Asociación para Evitar la Ceguera en México | Withdrawn | No outcome recorded |
| Phase 3 | NCT00565019 | Nov 2007 → Aug 2011 | palmar fibromatosis | Sunnybrook Health Sciences Centre | Completed | No outcome recorded |
| Phase 3 | NCT00532415 | Sep 2007 | — | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT00444600 | Mar 2007 → Dec 2009 | diabetic macular edema | Jaeb Center for Health Research | Completed | Mixed |
| Phase 3 | NCT00370539 | Sep → Nov 2006 | wet macular degeneration | Shahid Beheshti University of Medical Sciences | Unknown | No outcome recorded |
| Phase 3 | NCT00309192 | Apr 2006 → Jul 2009 | diabetic macular edema, type 2 diabetes mellitus | Institute of Applied Ophthalmobiology - IOBA | Completed | No outcome recorded |
| Phase 3 | NCT00344942 | Apr 2006 → Apr 2007 | rhinitis | Sanofi | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT00370669 | Nov 2005 → Feb 2007 | diabetic macular edema | Shahid Beheshti University of Medical Sciences | Unknown | Met primary |
| Phase 3 | NCT00242580 | Sep 2005 → Jan 2008 | age-related macular degeneration, choroidal neovascularization | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00105404 | Mar 2005 → Oct 2006 | diabetic macular edema | National Eye Institute (NEI) | Completed | No outcome recorded |
| Phase 3 | NCT00106132 | Mar → Nov 2005 | cystoid macular edema, retinal vein occlusion | National Eye Institute (NEI) | Completed | No outcome recorded |
| Phase 3 | NCT00100009 | Dec 2004 → Dec 2006 | macular degeneration | National Eye Institute (NEI) | Completed | No outcome recorded |
| Phase 3 | NCT00367133 | Jul 2004 → May 2008 | diabetic macular edema | Jaeb Center for Health Research | Completed | Missed primary |
| Phase 3 | NCT00132925 | Nov 2003 → Feb 2006 | perennial allergic rhinitis | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00373282 | Jun 2001 → Jun 2003 | proliferative vitreoretinopathy | Shahid Beheshti University of Medical Sciences | Completed | No outcome recorded |
| Phase 439 trials · 1 met primary · 1 missed | ||||||
| Phase 4 | NCT06935877 | Apr 2025 → Jun 2026 overdue | bursitis | Shin Kong Wu Ho-Su Memorial Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06897969 | Apr → Sep 2025 overdue | keloid | Nishtar Medical University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06801587 | Feb → May 2025 | — | Fang Luo | Completed | No outcome recorded |
| Phase 4 | NCT06782529 | Jan 2025 → Jan 2027 expected | osteoarthritis, knee | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 4 | NCT06779396 | Jan → Mar 2025 overdue | — | Beijing Tiantan Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT07006168 | Nov 2024 → Dec 2026 expected | — | The University of Hong Kong | Recruiting | No outcome recorded |
| Phase 4 | NCT04895280 | Nov 2024 → Nov 2026 | rotator cuff syndrome, tendinitis | Michael Khazzam | Withdrawn | No outcome recorded |
| Phase 4 | NCT06362005 | May 2024 → Jul 2025 | lichen planus, oral | Al-Azhar University | Completed | No outcome recorded |
| Phase 4 | NCT05806021 | Jan 2024 → Dec 2025 overdue | osteoarthritis, knee | University of Montreal Hospital Centre (CHUM) | Recruiting | No outcome recorded |
| Phase 4 | NCT06084364 | Nov 2023 → Jan 2027 expected | osteoarthritis, hand | Diakonhjemmet Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT06069804 | Oct → Dec 2023 | — | Beijing Tiantan Hospital | Completed | No outcome recorded |
| Phase 4 | NCT05178485 | Jul 2023 → Dec 2024 | — | University of Texas Southwestern Medical Center | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT06882551 | Apr → Nov 2023 | diabetic macular edema | Khyber Teaching Hospital | Completed | No outcome recorded |
| Phase 4 | NCT04075136 | Mar 2023 → Nov 2024 | wet macular degeneration | Wake Forest University Health Sciences | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT05436535 | Nov 2022 → Apr 2025 | atopic eczema | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 4 | NCT05336968 | Sep 2022 → Nov 2025 | osteoarthritis, knee | United Health Services Hospitals, Inc. | Unknown | No outcome recorded |
| Phase 4 | NCT05292677 | Jul 2021 → Jun 2023 | laryngeal disorder | Eastern Virginia Medical School | Unknown | No outcome recorded |
| Phase 4 | NCT04641351 | May 2021 → Aug 2026 overdue | osteoarthritis, knee, synovitis | The Cleveland Clinic | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04786210 | Jan 2021 → Dec 2022 | keloid | NYU Langone Health | Completed | No outcome recorded |
| Phase 4 | NCT03991936 | Mar 2020 → Mar 2023 | nail disorder, psoriasis | Weill Medical College of Cornell University | Completed | No outcome recorded |
| Phase 4 | NCT04701593 | Jan 2020 → Oct 2022 | retinal detachment | Virginia Polytechnic Institute and State University | Completed | No outcome recorded |
| Phase 4 | NCT04228029 | Aug 2019 → Feb 2020 | alopecia areata | Kasr El Aini Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT04003376 | Jul 2019 → Jul 2021 | alopecia areata | Assiut University | Unknown | No outcome recorded |
| Phase 4 | NCT03914092 | Jun 2019 → Aug 2022 | — | Assiut University | Completed | No outcome recorded |
| Phase 4 | NCT05139667 | May 2019 → Oct 2021 | lichen planus, oral | Ain Shams University | Completed | No outcome recorded |
| Phase 4 | NCT03995641 | Feb 2019 → Sep 2023 | pelvic organ prolapse | Kettering Health Network | Withdrawn | No outcome recorded |
| Phase 4 | NCT04498260 | Jan 2019 → Mar 2021 | — | Cancer Institute of the State of São Paulo | Unknown | No outcome recorded |
| Phase 4 | NCT03640650 | Aug 2018 → Mar 2021 | cataract | PeriPharm | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT03895840 | Mar 2018 → May 2021 | osteoarthritis, knee | University of Kansas Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT03291197 | Oct 2017 → Oct 2018 | complex regional pain syndrome | Ottawa Hospital Research Institute | Completed | Met primary |
| Phase 4 | NCT03105674 | May → Nov 2017 | anal fistula, hemorrhoid, ulcer of anus and rectum | Columbia University | Withdrawn | No outcome recorded |
| Phase 4 | NCT04115644 | May → Sep 2017 | rotator cuff syndrome | Michael Khazzam | Terminated | No outcome recorded |
| Phase 4 | NCT02806752 | Jan 2017 → Dec 2018 | wet macular degeneration | Aier School of Ophthalmology, Central South University | Unknown | No outcome recorded |
| Phase 4 | NCT02858297 | May 2015 → Jun 2016 | lichen planus, oral | Ain Shams University | Completed | No outcome recorded |
| Phase 4 | NCT01238536 | Apr 2011 → Aug 2013 | spinal stenosis | University of Washington | Completed | Missed primary |
| Phase 4 | NCT01230424 | Mar 2011 → Jan 2015 | osteoarthritis, knee | Tufts Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01154153 | Jun → Oct 2010 | allergic rhinitis | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT00779792 | Sep → Nov 2008 | occupational dermatitis | Odense University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00554476 | Jan 2003 → Apr 2006 | epicondylitis | Azad University of Medical Sciences | Terminated | No outcome recorded |
| Phase not applicable36 trials · 1 missed | ||||||
| — | NCT07660120 | Jul 2026 → Jul 2027 expected | reactive cutaneous fibrous lesion | University of California, Davis | Not yet recruiting | No outcome recorded |
| — | NCT07201766 | Dec 2025 → Feb 2026 overdue | keloid | King Edward Medical University | Not yet recruiting | No outcome recorded |
| — | NCT07409571 | Oct 2025 → May 2026 overdue | gingival recession | Kahramanmaras Sutcu Imam University | Recruiting | No outcome recorded |
| — | NCT06761768 | Aug 2025 → Jul 2026 overdue | arthritis, sacroiliac | Tri-Service General Hospital (TSGH) | Not yet recruiting | No outcome recorded |
| — | NCT07042282 | Aug 2025 → Aug 2027 expected | carpal tunnel syndrome, rheumatic disorder | Yun Qian | Not yet recruiting | No outcome recorded |
| — | NCT07043179 | Jul 2025 → Jul 2027 expected | carpal tunnel syndrome | Yun Qian | Not yet recruiting | No outcome recorded |
| — | NCT07420166 | Jan → Jun 2025 | keloid | Muhammad Aamir Latif | Completed | No outcome recorded |
| — | NCT06407180 | Jul 2024 → Dec 2026 expected | — | Teeradon Waewworawit | Not yet recruiting | No outcome recorded |
| — | NCT07471997 | Jun 2024 → Feb 2025 | disease of orbital part of eye adnexa | Instituto de Oftalmología Fundación Conde de Valenciana | Completed | No outcome recorded |
| — | NCT06327581 | Dec 2023 → Dec 2026 expected | alopecia areata | Zagazig University | Recruiting | No outcome recorded |
| — | NCT06088147 | Dec 2023 → Mar 2024 | alopecia areata | Al-Azhar University | Unknown | No outcome recorded |
| — | NCT06798025 | Jul 2023 → Jun 2024 | stenosis of lacrimal punctum | Tanta University | Completed | No outcome recorded |
| — | NCT07567118 | May 2023 → Jan 2025 | cataract | Damascus University | Completed | No outcome recorded |
| — | NCT04574232 | Jan 2023 → Dec 2024 | — | Central Hospital, Nancy, France | Unknown | No outcome recorded |
| — | NCT05165875 | Jun 2022 → Feb 2024 | de Quervain disease | National University Hospital, Singapore | Unknown | No outcome recorded |
| — | NCT04959721 | Jul → Sep 2021 | — | Min Cheol Chang | Unknown | No outcome recorded |
| — | NCT05345808 | Mar 2021 → Feb 2022 | retinal vein occlusion | Al-Azhar University | Completed | No outcome recorded |
| — | NCT04812626 | Jan → Aug 2021 | keloid | B.P. Koirala Institute of Health Sciences | Completed | No outcome recorded |
| — | NCT05428683 | Dec 2020 → Aug 2021 | — | Emad Abdel Aal Saliem | Completed | No outcome recorded |
| — | NCT04627402 | Nov 2020 → Jun 2021 | diabetic macular edema, type 2 diabetes mellitus | Zhongshan Ophthalmic Center, Sun Yat-sen University | Unknown | No outcome recorded |
| — | NCT04364425 | May 2020 → Sep 2021 | frozen shoulder | Taipei Veterans General Hospital, Taiwan | Unknown | No outcome recorded |
| — | NCT05038072 | Jul 2019 → Nov 2020 | macular retinal edema, retinal vein occlusion | Damascus University | Completed | No outcome recorded |
| — | NCT04812977 | Jun → Dec 2018 | central retinal vein occlusion with macular edema | Hayatabad Medical Complex | Completed | No outcome recorded |
| — | NCT03431961 | Mar 2018 → Feb 2019 | allergic asthma | Gail Gauvreau | Unknown | No outcome recorded |
| — | NCT03365141 | Nov 2017 → Sep 2018 | vitiligo | The Catholic University of Korea | Unknown | No outcome recorded |
| — | NCT03072290 | Feb 2017 → Nov 2018 | carpal tunnel syndrome | Taipei Veterans General Hospital, Taiwan | Completed | No outcome recorded |
| — | NCT02939482 | Oct 2016 → Aug 2018 | radiculopathy, spinal stenosis, spondylosis | Navamindradhiraj University | Completed | No outcome recorded |
| — | NCT02781818 | Jun 2016 → Jun 2017 | hidradenitis suppurativa | University of North Carolina, Chapel Hill | Completed | Missed primary |
| — | NCT02996097 | Apr 2016 → Jun 2018 | keloid | Johns Hopkins University | Completed | No outcome recorded |
| — | NCT02457026 | Jan 2016 → Jan 2018 | wet macular degeneration | Duke University | Withdrawn | No outcome recorded |
| — | NCT03132051 | Apr 2013 → Feb 2018 | carpal tunnel syndrome | Taipei Veterans General Hospital, Taiwan | Unknown | No outcome recorded |
| — | NCT01736670 | Apr → May 2012 | — | Patel, Rita Vikram, M.D. | Completed | No outcome recorded |
| — | NCT00924508 | Jul 2008 → Sep 2011 | dermatitis | University of California, San Francisco | Terminated | No outcome recorded Stop: Business |
| — | NCT00789971 | Mar 2007 → Mar 2008 | eye adnexa disorder | Sligo General Hospital | Completed | No outcome recorded |
| — | NCT00447031 | Mar → Nov 2007 | macular degeneration | Yonsei University | Withdrawn | No outcome recorded |
| — | NCT00238563 | — | glaucoma | Stanford University | Withdrawn | No outcome recorded Stop: Business |
| Comparator or background therapy221 trials | ||||||
| Phase 0 | NCT04645303 Comparator | Nov 2020 → Apr 2021 | arthropathy | Dubai Health Authority | Unknown | No outcome recorded |
| Phase 0 | NCT04336488 Comparator | Jan → Jun 2020 | oral erosive lichen | Jaylane kadry Ghonima | Unknown | No outcome recorded |
| Phase 0 | NCT03415165 Comparator | Jan 2018 → Jan 2019 | lichen planus, oral | Cairo University | Unknown | No outcome recorded |
| Phase 0 | NCT02031367 Comparator | Mar 2014 → Dec 2016 | pes anserinus tendinitis or bursitis | C.R.Darnall Army Medical Center | Unknown | No outcome recorded |
| Phase 0 | NCT01382771 Comparator | Oct 2010 → Sep 2012 | — | University of Florida | Completed | No outcome recorded |
| Show all 221 trials opens the full record — a long page | ||||||
News releases announcing trial results or a regulatory action · 10
| Date | Issuer | Release |
|---|---|---|
| 2026-03-03 | Harrow Inc | Regulatory Harrow to Initiate Phase 3 Clinical Trial Seeking to Expand TRIESENCE® Label to Include Ocular Inflammation and Pain Following Cataract Surgery Indication harrow.com ↗
today announced that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application |
| 2025-10-01 | Alembic Pharmaceuticals Ltd. | Regulatory 18th October, 2025 Vadodara, India alembicpharmaceuticals.com ↗
Alembic Pharmaceuticals Limited announces USFDA Final Approval for Triamcinolone Acetonide Injectable Suspension USP, 40 mg/mL (Single-Dose and Multiple-Dose Vials). |
| 2025-03-24 | Harrow Inc | Regulatory Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL harrow.com ↗
CMS will now separately reimburse TRIESENCE at the Average Sales Price (ASP) plus 6% in both ASC and HOPD settings. |
| 2016-10-25 | Harrow Inc | Results Imprimis' Dropless Therapy Shows Significant Advantages in a Large Peer-Reviewed Study harrow.com ↗
The study evaluated 1,541 eyes from 922 patients and demonstrated that in nearly 92% of cases (n=1413/1541), supplemental medication was not required after surgery. |
| 2016-07-22 | Harrow Inc | Results Peer-Reviewed Study of Dropless Cataract Surgery Shows 'Measurable Benefits' Compared to Drops harrow.com ↗
In the following month, Tri-Moxi-Vanc and drops produced no statistically significant difference in intraocular pressure immediately ( P =0.81) or over time ( P =0.74), central macular thickness at 1 week and 1 month ( P =0.18), central corneal thickness ( P =0.92), or reported pain ( P =0.67). |
| 2016-05-12 | Harrow Inc | Results Clinical Study of Imprimis Pharmaceuticals' Tri-Moxi-Vanc Dropless Therapy Formulation Show Statistically Significant Reduction in Cystoid Macular Edema in Patients Following Cataract Surgery harrow.com ↗
The CME rate was 0.5% in the group (n=600) receiving Dropless Therapy (intravitreal Tri-Moxi-Vanc) with post-operative NSAID drops only, thereby achieving statistical significance (P=0.003) in CME prevention versus traditional steroid and NSAID drops. |
| 2015-04-16 | Perrigo Company | Regulatory Perrigo Announces The Launch Of A Generic Version Of Kenalog® Nasal Spray perrigo.com ↗
today announced that it has received final Federal Drug Administration approval for Triamcinolone Acetonide Topical Aerosol, the generic version of Sun Pharma's Kenalog® nasal spray. |
| 2015-02-03 | Harrow Inc | Results Imprimis Pharmaceuticals and Cleveland Eye Clinic Announce Positive Findings of Evaluation of LessDrops™ Combination Eye Drop Formulations Following LASIK Surgery harrow.com ↗
Dr. Wiley concluded that Imprimis' Tri-Moxi and Pred-Moxi combination eye drop formulations produced equivalent outcomes compared to standard follow-up care measurements observed in traditional post-LASIK eye drop treatments. |
| 2014-10-24 | Harrow Inc | Results Imprimis Pharmaceuticals Reports on Positive Clinical Findings Presented at the American Academy of Ophthalmology (AAO) Annual Meeting harrow.com ↗
SAN DIEGO , Oct. 24, 2014 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical compounded drug formulations, today reported on clinical findings demonstrating the safety and benefits of Dropless cataract surgery and provided an update resulting from the recent American Academy of Ophthalmology (AAO) annual meeting held in Chicago , Illinois. |
| 2009-08-03 | Perrigo Company | Regulatory Perrigo Announces FDA Approval for Generic Version of NASACORT® AQ perrigo.com ↗
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its partner Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) (previously Barr Laboratories Inc.) has received final approval from the U.S. Food and Drug Administration to market Triamcinolone Acetonide Nasal Spray containing a paragraph IV certification. |
All press releases naming this drug 12 releases
Evidence & citations 52 cited values
Every value below carries the sentence it was read from. 408 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Triamcinolone acetonide | “The intervention was 0.1% triamcinolone acetonide adhesive paste (Kenacort A Orabase - Dermapharm) and 400 mg Vitamin E capsule (Vitamin E 400 - Pharopharmaceuticles) for the...” NCT04126720 ↗363“Local corticosteroid injection in group I: 1 ml of triamcinolone acetonide (40 milligram/1.0 mL) was locally injected in the wrist using a 25-gauge needle, which was slowly...” NCT06209957 ↗ “FX006 is a novel, microsphere-based, extended-release formulation of triamcinolone acetonide for intraarticular (IA) injection designed to maintain treatment concentration in...” PMID 29088579 ↗ Dec 2017 “INTRODUCTION: The aim of this work is to assess the safety and efficacy of repeat administration of triamcinolone acetonide extended-release (TA-ER) in patients with...” PMID 30741382 ↗ Feb 2019 “At the end of surgery, 4mg triamcinolone acetonide and 0.2mg moxifloxacin from 0.5 moxifloxacin preservative-free eye drop) were injected once inferotemporally 3.5 mm posterior...” NCT05428683 ↗ “Patients requiring a corticosteroid injection were prospectively randomized into two cohorts to receive a corticosteroid (triamcinolone acetonide) combined with either...” PMID 33760691 ↗ Apr 2021 “Where patients are treated with topical corticosteroids 1 mg/g Triamcinolone acetonide (Kenacort-A orabase 20 G Pomad: Deva dermatological product,Turkey) applied topically 4...” NCT03415165 ↗ “The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study: Two Randomized Trials to Compare the Efficacy and Safety of Intravitreal Injection(s) of...” NCT00105027 ↗ “the relative efficacy of the steroids triamcinolone acetonide and clobetasol, the topical immune modulator tacrolimus, a 20% Glycerol ointment compared with an inert ointment...” NCT00779792 ↗ “Recommended TCS include triamcinolone acetonide 0.1% cream or fluocinolone acetonide 0.025% ointment as medium potency topical corticosteroids and hydrocortisone 1% cream as...” NCT03568318 ↗ “Both will underwent median nerve hydro-dissection using 1% lidocain followed by group I injection of Sodium hyaluronate and group II injection of 40 mg of triamcinolone...” NCT03180125 ↗ |
| Known as | Adcortyl | “Drug: Adcortyl” NCT01524744 ↗ |
| Known as | Aristocort C | “This study is a randomized, intraindividual study to evaluate the short-term efficacy of triamcinolone acetonide (Aristocort® C) in subjects with atopic dermatitis.” NCT05844618 ↗1“Triamcinolone Acetonide (Aristocort® C)” NCT07283874 ↗ |
| Known as | CLS-TA | “This open-label study is designed to evaluate the safety of suprachoroidally administered triamcinolone acetone injectable suspension, CLS-TA, in patients with non-infectious...” NCT03097315 ↗2“40 mg/mL CLS-TA, Clearside's formulation of TA (CLS-TA, triamcinolone acetonide injectable suspension)” NCT02303184 ↗ “40 mg/mL CLS-TA, Clearside's formulation of TA (CLS-TA, triamcinolone acetonide injectable suspension)” NCT02255032 ↗ |
| Known as | Epirelefan | “triamcinolone acetonide injectable suspension (Epirelefan®, 40mg/ ml, Eipico, Egypt)” NCT06327581 ↗ |
| Known as | FX006 | “FX006 is a novel, microsphere-based, extended-release formulation of triamcinolone acetonide for intraarticular (IA) injection designed to maintain treatment concentration in...” PMID 29088579 ↗ Dec 2017 |
| Known as | ITA | “intravitreal triamcinolone acetonide (ITA)” PMID 19748675 ↗ Sep 2009 |
| Known as | IVT | “comparing intravitreal bevacizumab (IVB) injection alone or in combination with intravitreal triamcinolone acetonide (IVT) versus macular laser photocoagulation (MPC) as a...” PMID 22234244 ↗ Feb 2012 |
| Known as | IVTA | “BACKGROUND: We would assess the efficacy of intravitreal injection of triamcinolone acetonide IVTA combined with standard phacoemulsification on the central subfield macular...” PMID 36401233 ↗ Nov 20221“IMPORTANCE: The Standard of Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study showed that intravitreal triamcinolone acetonide (IVTA) is effective at reducing...” PMID 26086920 ↗ Sep 2015 |
| Known as | kenacort | “Injection with 40mg triamcinolone acetonide (kenacort) in the wrist” NCT04755127 ↗ |
| Known as | Kenacort TM | “The patients were administered topical corticosteroids in the form of a 0.1% triamcinolone acetonide preparation (Kenacort TM 0.1% Abbott).” NCT06681090 ↗ |
| Known as | Kenacort-A | “Where patients are treated with topical corticosteroids 1 mg/g Triamcinolone acetonide (Kenacort-A orabase 20 G Pomad: Deva dermatological product,Turkey) applied topically 4...” NCT03415165 ↗3“1 mL of triamcinolone acetonide 40 mg (KENACORT-A IM/Intra-articular Retard 40 mg ampoule) and 1 mL of 2% lidocaine (Aritmal 2% ampoule) will be injected over the plantar fascia.” NCT07120204 ↗ “Triamcinolone Acetonide ointment, Kenacort-A orabase” NCT06533033 ↗ |
| Known as | Kenacort-A Orabase | “The intervention was 0.1% triamcinolone acetonide adhesive paste (Kenacort A Orabase - Dermapharm) and 400 mg Vitamin E capsule (Vitamin E 400 - Pharopharmaceuticles) for the...” NCT04126720 ↗1“triamcinolone acetonide 1% oral gel "Kenacort-A Orabase"” NCT05787925 ↗ |
| Known as | Kenacort-AⓇ | “Combination of intravitreal triamcinolone acetonide (Kenacort-AⓇ) (2mg/0.05ml) and intravitreal bevacizumab (Avastin®) (1.25mg/0.05ml)” NCT04812977 ↗ |
| Known as | Kenacourt-A Orabase | “0.1% topical triamcinolone Acetonide preparation "Kenacourt-A Orabase"” NCT06681090 ↗ |
| Known as | Kenacourt-A Orabase Pomad | “0.1 % topical triamcinolone acetonide preparation (Kenacourt-A Orabase Pomad, DEVA HOLDINGS A.S., Istanbul, Turkey) was used where the patients' were instructed to apply the...” NCT03572959 ↗ |
| Known as | Kenalog | “Participants will receive one ultrasound-guided injection with 1 ml Kenalog 40mg/ml and 1 ml Lidocaine 10mg/ml superficial to the insertion of the gluteus medius and minimus...” NCT06456099 ↗35“Epidural steroid injectate will be 2cc of 1% lidocaine followed by 1-3 cc of 40 mg/cc Kenalog (i.e. 40-120 mg Kenalog) or an equivalent steroid medication (depo-medrol 60-120...” NCT01238536 ↗ “heparin sulphate 40,000 IU (4 cc of 10,000 units/cc), lidocaine 2% 16 ml, Sodium bicarbonate 8.4% 4 ml and Kenalog 40 mg (1cc) to reach a total fluid volume of 25 ml will be...” NCT02870738 ↗ “Material identification: Celestone soluspan or Kenalog 1% 50mL multiuse vials without epinephrine, 1% 5mL lidocaine vials, 10mL syringes with 21mm x 1 ¼ inch needles, alcohol...” NCT03445611 ↗ “5 milliliters (mL) injection of corticosteroid (1cc Kenalog, 4cc Xylocaine) Kenalog - 40 (triamcinolone acetonide injectable suspension, USP) Xylocaine - MPF (lidocaine HCl...” NCT06793982 ↗ “* Trigger finger/De Quervain's tenosynovitis/Tendonitis: 20mg kenalog (0.5mL of kenalog 40mg/mL suspension) + 5mg lidocaine (0,5mL 10mg/mL lidocaine solution)” NCT06188221 ↗ “Patients assigned to Steroid group will receive 80mg of Triamcinolone Acetonide (Kenalog) mixed with 8mL of 1% lidocaine with epinephrine 1:100,000.” NCT03319784 ↗ “The corticosteroid is prepared in a 10 ml syringe by combining 1-2 mL Kenalog \[40 mg/dL\], 6-8 mL sterile normal saline, 3-4 mL Ropivicaine 1%.” NCT05288725 ↗ “The triamcinolone preparation commonly injected into the eye is Kenalog and is FDA-approved only for use in muscles and joints.” NCT00105027 ↗ “A 6ml solution of 4ml 0.25% Bupivacaine, 1ml 40mg Kenalog, and 1ml 4mg Dexamethasone will be prepared.” NCT01688362 ↗ “Participants in the corticosteroid group will recieve corticosteroid injections (1 cc Kenalog 10 mg).” NCT01897259 ↗ |
| Known as | Kenalog - 40 | “5 milliliters (mL) injection of corticosteroid (1cc Kenalog, 4cc Xylocaine) Kenalog - 40 (triamcinolone acetonide injectable suspension, USP) Xylocaine - MPF (lidocaine HCl...” NCT06793982 ↗3“5 milliliters (mL) injection of corticosteroid (1cc Kenalog, 4cc Xylocaine) Kenalog - 40 (triamcinolone acetonide injectable suspension, USP) Xylocaine - MPF (lidocaine HCl...” NCT06703970 ↗ “Subjects in the Experimental Group will received a 2 mL injection consisting of 1 mL of 0.5% bupivacaine (5 mg bupivacaine-HCL) and 1 mL Kenalog-40 (40 mg triamcinolone acetonide).” NCT05178485 ↗ “Name: Kenalog®-40 (triamcinolone acetonide injectable suspension)” NCT06478186 ↗ |
| Known as | Kenalog in orabase | “Kenalog in orabase (Triamcinolone acetonide 0.1% oral paste 5g)” NCT06910579 ↗ |
| Known as | Kenalog-10 | “Intralesional injections of 4mLs Triamcinolone Acetonide 10 mg/mL (Kenalog-10) on the whole scalp” NCT01797432 ↗2“5ml 1% Lidocaine + 1ml 40mg Kenalog®-10 into the shoulder joint” NCT00742846 ↗ “Triamcinolone Acetonide 10 mg/mL (Kenalog-10)” NCT00484679 ↗ |
| Known as | Nasacort AQ | “Subjects will also be given the nasal steroid Nasacort AQ (triamcinolone acetonide) at a dosage of 220 mcg.” NCT00665977 ↗1“Triamcinolone acetonide aqueous (TAA-AQ) nasal spray (NASACORT AQ)” NCT01154153 ↗ |
| Known as | RETAAC | “Phase I/II study with intravitreal triamcinolone acetonide microspheres(RETAAC)for treatment of diffuse diabetic macular edema unresponsive to laser photocoagulation.” NCT00407849 ↗ |
| Known as | SCS-TA | “A novel triamcinolone acetonide (TA) injectable suspension formulated for administration to the SCS, SCS-TA (Xipere®; Bausch + Lomb), received FDA approval in 2021 for the...” PMID 36787524 ↗ Feb 2023 |
| Known as | SCTA | “OBJECTIVE: To determine the efficacy of intravitreal bevacizumab (IVB) monotherapy versus a combination of IVB and suprachoroidal triamcinolone acetonide (SCTA) followed by...” PMID 42369925 ↗ Jun 2026 |
| Known as | Shincort | “The steroid injection was using 1ml of 10 mg (10mg/ml) triamcinolone acetonide (Shincort) mixed with 1 ml of 2% lidocaine hydrochloride (Xylocaine).” NCT02708693 ↗1“ultrasound guided steroid injection using 1ml of 10mg triamcinolone acetonide (Shincort) mixed with 1ml of 2% lidocaine hydrochloride (Xylocaine)” NCT04346030 ↗ |
| Known as | sinakort-A | “The following drugs will be used for this procedure: 80mg/2ml triamcinolone acetonide (sinakort-A) and 1 mL 0.5% bupivacaine (marcaine)” NCT04212949 ↗ |
| Known as | Stacort-A | “Stacort-A Triamcinolone Acetonide 40mg” NCT07006168 ↗ |
| Known as | TA-ER | “INTRODUCTION: The aim of this work is to assess the safety and efficacy of repeat administration of triamcinolone acetonide extended-release (TA-ER) in patients with...” PMID 30741382 ↗ Feb 20192“Triamcinolone acetonide extended-release (TA-ER) suspension is novel and composed of polylactic-co-glycolic acid microspheres which allows for timed release of the steroid over...” NCT06237153 ↗ “Name: ZILRETTA (triamcinolone acetonide extended-release injectable suspension; TA-ER)” NCT06478186 ↗ |
| Known as | TA-IR | “Active Ingredient: Triamcinolone Acetonide- Immediate Release (TA-IR)” NCT06478186 ↗ |
| Known as | TAA AQ | “This study was designed to determine the effect of 6-week triamcinolone acetonide aqueous (TAA-AQ) nasal spray treatment on HPA axis function” PMID 24717794 ↗ Mar 20142“patients were randomized to receive triamcinolone acetonide aqueous nasal spray (TAA AQ), 110 microg once daily, or placebo.” PMID 19441606 ↗ Apr 2009 “Triamcinolone acetonide (TAA-AQ) in the double-blind treatment period” NCT00449072 ↗ |
| Known as | TAAC | “For transition to suprachoroidal injection of Triamcinolone Acetone (TAAC) a diagnosis of resistant DME is required.” NCT04690608 ↗ |
| Known as | TAC | “OBJECTIVE: To compare levels of triamcinolone acetonide (TAC) in perilymph and plasma after intratympanic injection.” PMID 34591079 ↗ Nov 20213“Triamcinolone Acetanoide (TAC) which is the existing standard of care in sub-Saharan Africa” NCT04391621 ↗ “the current approved steroid treatment for keloids, triamcinolone acetonide (TAC)” NCT01978301 ↗ “Group A: Intralesional (IL) triamcinolone acetonide (TAC) alone;” NCT04812626 ↗ |
| Known as | TAC DuraPeel | “Triamcinolone Acetonide (TAC) DuraPeel” NCT00890968 ↗ |
| Known as | TAC-PF | “The purpose of this study is to evaluate the long-term safety and potential efficacy of novel intravitreal injections of a preservative-free formulation of triamcinolone...” NCT00101764 ↗3“preservative-free intravitreal formulation of triamcinolone acetonide (TAC-PF)” NCT00100009 ↗ “Preservative-Free Triamcinolone Acetonide (TAC-PF)” NCT00464347 ↗ “Triamcinolone Acetonide (TAC-PF)” NCT00071227 ↗ |
| Known as | TCA | “This open-label, parallel-arm, healthy volunteer study assessed potential short-term safety, tolerability and pharmacokinetic (PK) interactions between IA LOR and triamcinolone...” PMID 37902943 ↗ Oct 2023 |
| Known as | TCA-ER | “triamcinolone acetonide extended-release injectable suspension; TCA-ER” NCT06478186 ↗ |
| Known as | TCA-IR | “Cohort E: Triamcinolone acetonide immediate-release (TCA IR) 40 mg, Final Visit Week 12” NCT02003365 ↗1“Triamcinolone Acetonide- Immediate Release;TCA-IR” NCT06478186 ↗ |
| Known as | TRI | “The study compared the clinical effectiveness of topical Tacrolimus (TAC) in patches or gel with Triamcinolone acetonide (TRI) gel for erosive/atrophic oral lichen planus (OLP)” PMID 36788511 ↗ Feb 2023 |
| Known as | Triamcinalone Acetonide | “preoperative Triamcinalone Acetonide (TA)” NCT00238563 ↗ |
| Known as | Triamcinolone | “Triamcinolone acetonide mucoadhesive films 1 mg every 6 hours for two weeks.” NCT02453503 ↗3“Intralesional injections of 0.4mg/cc triamcinolone once a week” NCT03365141 ↗ “Kenalog-40 (triamcinolone 40mg)” NCT02613455 ↗ “Kenalog (Triamcinolone)” NCT02519738 ↗ |
| Known as | Triamcinolone Acetanoide | “Triamcinolone Acetanoide (TAC) which is the existing standard of care in sub-Saharan Africa” NCT04391621 ↗ |
| Known as | triamcinolone acetonide 10mg/ml (shincort, YSP, Taiwan) | “triamcinolone acetonide 10mg/mL (Shincort®, YSP, Taiwan)” NCT01950793 ↗2“triamcinolone acetonide 10mg/ml (shincort, YSP, Taiwan)” NCT03072290 ↗ “triamcinolone acetonide 10mg/ml (Shincort, YSP, Taiwan)” NCT04364425 ↗ |
| Known as | Triamcinolone Acetonide Acetate and Urea Cream | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04994951 ↗ |
| Known as | Triamcinolone acetonide aqueous | “This study was designed to determine the effect of 6-week triamcinolone acetonide aqueous (TAA-AQ) nasal spray treatment on HPA axis function” PMID 24717794 ↗ Mar 2014 |
| Known as | triamcinolone acetonide extended-release | “INTRODUCTION: The aim of this work is to assess the safety and efficacy of repeat administration of triamcinolone acetonide extended-release (TA-ER) in patients with...” PMID 30741382 ↗ Feb 2019 |
| Known as | Triamsinolon asetonid | “% 0,1 Triamsinolon asetonid (Kenacort- A orabase pomad) will be used on ulcer areas 4 times a day (after meals and before going to bed) for 7 days.” NCT06839313 ↗ |
| Known as | Triescence | “and Triescence (triamcinolone acetonide) in treatment-naïve patients with Exudative Age-Related Macular Degeneration.” NCT04075136 ↗ |
| Known as | Xipere | “A novel triamcinolone acetonide (TA) injectable suspension formulated for administration to the SCS, SCS-TA (Xipere®; Bausch + Lomb), received FDA approval in 2021 for the...” PMID 36787524 ↗ Feb 2023 |
| Known as | Zilretta | “Triamcinolone acetonide extended-release (TA-ER) suspension is novel and composed of polylactic-co-glycolic acid microspheres which allows for timed release of the steroid over...” NCT06237153 ↗11“Generic Name: Triamcinolone acetonide Zilretta is an extended-release synthetic corticosteroid indicated as an intra-articular injection for the management ofosteoarthritis...” NCT05492851 ↗ “Zilretta (Triamcinolone acetonide extended-release injectable suspension) is indicated as an intra-articular injection for the management of pain due to knee OA.” NCT05058209 ↗ “Zilretta®, triamcinolone acetonide extended release suspension 32 mg, is a microsphere formulation of injectable steroid” NCT04831255 ↗ “Standard PAI + 32mg Zilretta (triamcinolone acetonide extended release injectable suspension)” NCT07151417 ↗ “Name: ZILRETTA (triamcinolone acetonide extended-release injectable suspension; TA-ER)” NCT06478186 ↗ |
| Action | Inhibit | “can inhibit the expression of VEGF” NCT05464953 ↗ |
| Modality | Other / unclassified | “The use of intravitreal injections of corticosteroid (triamcinolone acetonide) appears to be a promising treatment for a variety of ocular diseases associated with inflammation.” NCT00101764 ↗ |
| Route | Intravitreal | “receive via intravitreal injection” NCT00071227 ↗ |